Reckitt Benckiser sees modest bounce following $7.1 billion market-cap wipeout
By Steve Goldstein
Reckitt Benckiser saw modest gains on Monday, following the share-price slide that erased some GBP5.6 billion ($7.1 billion) of market value.
Reckitt Benckiser shares (UK:RKT) rose 1.4% in afternoon trade, after a decline of nearly 15% on Friday, when an Illinois jury ordered its Mead Johnson unit to pay $60 million in compensation for the death of a premature baby who was fed Enfamil. Reckitt said it will appeal the decision.
Related: Here's what families need to know after a landmark $60 million verdict in baby-formula suit
There are more than 400 lawsuits against Mead Johnson and Abbott pending in federal court in Chicago, according to Reuters. Analysts at Barclays said that number may grow, but plaintiff numbers would not likely exceed "a few thousand plaintiffs settling in the high hundreds of thousands of dollars a case."
Analysts at RBC Capital Markets led by James Edwardes Jones said a call with company executives was reassuring.
"Reckitt believes there were errors in the trial and that there is no evidence to support a causal relationship between its products and [necrotizing enterocolitis]. Indeed it is the case that breast milk offers the lowest incidence rates of NEC in pre-term infants, but when it (and donor breast milk) is unavailable, infant milk products are the next best thing," they said.
Analysts at Deutsche Bank said the maximum liability would be between GBP1.5 billion and GBP3.3 billion.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-18-24 1053ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations